Tokyo Tape
Sign in
← Seikagaku

Quarterly report · Q1

4548.TEDINET S100OYA7
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥8.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥34.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥11.8bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥1.1bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥4.4bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥5.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.6bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.7bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥4.6bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥1.5bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.7bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.7bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥75.0bnat 2022-06-30Cons.Assets
Total assets¥75.2bnat 2022-03-31Cons.Assets
Total assets¥75.4bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥7.7bnat 2022-06-30Cons.Liabilities
Total liabilities¥8.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥67.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥66.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥67.6bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥21.0bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥21.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥26.622022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥66.322021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.732021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio89.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio88.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.6%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q1r_E00970-000LALreportable segmentrevenue2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E00970-000LALreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E00970-000LALreportable segmentsegment profit2022-04-01 → 2022-06-30¥899m
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentsegment profit2022-04-01 → 2022-06-30¥227m
—segment totalrevenue2022-04-01 → 2022-06-30¥8.3bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥8.3bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.1bn
jpcrp040300-q1r_E00970-000LALreportable segmentrevenue2021-04-01 → 2021-06-30¥2.1bn
jpcrp040300-q1r_E00970-000LALreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.1bn
jpcrp040300-q1r_E00970-000LALreportable segmentsegment profit2021-04-01 → 2021-06-30¥500m
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentrevenue2021-04-01 → 2021-06-30¥9.7bn
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentrevenue external2021-04-01 → 2021-06-30¥9.7bn
jpcrp040300-q1r_E00970-000Pharmaceuticalreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.9bn
—segment totalrevenue2021-04-01 → 2021-06-30¥11.8bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥11.8bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥4.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 385
ItemContextValueUnit
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember9707000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember2076000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember11784000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration11784000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember9707000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember2076000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember11784000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration11784000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember3946000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember500000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember4446000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration4446000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember5488000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember2819000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember8307000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration8307000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember5488000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember2819000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember8307000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration8307000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E00970-000PharmaceuticalReportableSegmentsMember227000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E00970-000LALReportableSegmentsMember899000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember1126000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating incomeCurrentYTDDuration1126000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の4の7第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-08-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第77期第１四半期（自 2022年4月1日　至 2022年6月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)生化学工業株式会社
Company name in english cover pageFilingDateInstantSEIKAGAKU CORPORATION
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　水谷　建

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass